Pyrophosphate imaging agent shortage reported, could last weeks

The American Society of Nuclear Cardiology (ASNC) is alerting its provider members of a pyrophosphate shortage, which could potentially last for weeks. 

The ASNC has received reports of imaging agent 99mTechnetium-pyrophosphate (PYP) being in low supply, citing statements it received from two manufacturers, Curium and Sun Radiopharma, who blame the shortage on supply chain disruptions.

According to the ASNC, Curium said it is working to find an alternative supplier to resume normal production as soon as possible. In its own statement, Sun Radiopharma provided a “best estimate” of January 2024 for PYP production to resume as normal.

The company also lists shortages in other radiopharmaceutical products, with estimates for when supplies will be available. The full statement from Sun Radiopharma can be found here.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH.